Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Oncogene|September 2, 2018
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancerZachary A Yochum, Jessica Cades, Hailun Wang, et al.
Molecular and Cellular Biology|February 17, 2005
DR5 knockout mice are compromised in radiation-induced apoptosisNiklas Finnberg, Joshua J Gruber, Peiwen Fei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Lung Cancer (Amsterdam, Netherlands)|November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancerDavid E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, et al.
Cancer|May 5, 2017
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancerAhmad A Tarhini, Imran Rafique, Theofanis Floros, et al.
Neoplasia (New York, N.Y.)|January 28, 2015
Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cellsRajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, et al.
Cancer Research Communications|June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
Time-Resolved Crystallography Reveals the Mechanisms of GTP hydrolysis for N-RAS and the Oncogenic Mutants G12C, G12V and Q61LGuowu Lin, Paola Zinser-Peniche, Xiaohong Zhou, et al.
The Journal of Clinical Investigation|December 18, 2025
MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtypeTimothy F Burns, Sanja Dacic, Anish Chakka, et al.
Pageof 7